- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02616705
Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis
January 3, 2022 updated by: Lewis R. Roberts, Mayo Clinic
Immunoglobulin G4-related disease (IgG4-RD) is an uncommon inflammatory disorder that may affect multiple organ systems, including the biliary tree.
IgG4-sclerosing cholangitis (IgG4-SC) can be difficult to distinguish from primary sclerosing cholangitis (PSC) or cholangiocarcinoma (CCA).
The investigators aim to evaluate the sensitivity and specificity of bile for the diagnosis of IgG4-SC.
Bile samples of patients with biliary strictures of various causes, including IgG4-SC, PSC, and CCA, will be collected during clinical cholangiography procedures.
IgG4 will be measured in bile specimens and bile IgG4 concentrations compared between IgG4-SC, PSC, CCA, and other types of biliary strictures.
Study Overview
Status
Completed
Detailed Description
This study will recruit cases from Mayo Clinic Rochester and Japanese institutions such as Nagoya City University Hospital, Nagoya Daini Red Cross Hospital, and Kurashiki Central hospital.
Participants will be individuals who will receive endoscopic retrograde cholangiography (ERC), endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) or percutaneous transhepatic cholangiography (PTC).
Bile samples collected from the target cases will be assayed for IgG4 concentration.
Study Type
Observational
Enrollment (Actual)
511
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nagoya, Japan
- Nagoya City Universty Graduate School of Medical Sciences
-
-
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Cases with biliary stricture(s) of any cause
Description
Inclusion Criteria:
- The presence of a biliary stricture
- 18 years and older
- Consented to IRB 707-03
Exclusion Criteria:
- Younger than 18 years of age
- Unable to collect a bile sample
- Abnormal postsurgical anatomy preventing collection of a bile sample
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
IgG4-related sclerosing cholangitis
Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)
|
Controls
cholangiocarcinoma, PSC, and other patients with biliary strictures
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability of bile IgG4 concentration to distinguish between IgG4-SC, PSC, and CCA.
Time Frame: 2 year
|
Bile concentration of IgG4 will be measured in cases and controls, and the groups will be compared using appropriate statistical methods
|
2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between bile and serum IgG4 concentrations.
Time Frame: 2 years
|
The relationship between Bile and serum IgG4 concentrations will be assessed for case and controls, using appropriate statistical methods
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lewis R Roberts, MB, ChB, PhD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Actual)
September 30, 2019
Study Completion (Actual)
September 30, 2019
Study Registration Dates
First Submitted
November 23, 2015
First Submitted That Met QC Criteria
November 27, 2015
First Posted (Estimate)
November 30, 2015
Study Record Updates
Last Update Posted (Actual)
January 5, 2022
Last Update Submitted That Met QC Criteria
January 3, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-004819
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
Data sharing could be arranged and will require IRB approval
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IgG4-related Disease
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers Squibb; Rho Federal Systems Division, Inc.; Autoimmunity Centers...TerminatedIgG4 Related Disease | IgG4-RDUnited States
-
Peking Union Medical College HospitalRecruiting
-
Meir Medical CenterUnknown
-
Peking Union Medical College HospitalRecruiting
-
Meir Medical CenterCompletedUndiagnosed IgG4 Related DiseasesIsrael
-
Zenas BioPharma (USA), LLCRecruitingIgG4 Related DiseaseUnited States, Korea, Republic of, Spain, Japan, France, Poland, Taiwan, Italy, United Kingdom, Argentina, Netherlands, Turkey, Hong Kong, Sweden, Hungary, Germany, Mexico
-
Matthew C. BakerStanford UniversityRecruiting
-
AmgenActive, not recruitingIgG4 Related DiseasePoland, Spain, United States, Argentina, Australia, Canada, China, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Sweden, Turkey, United Kingdom
-
Beijing Friendship HospitalNot yet recruiting